ClinicalTrials.gg
Active, not recruitingNCT06565611BMT-801Updated Mar 6, 2025

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

A Phase 2 interventional study of bremelanotide and tirzepatide in Obesity, sponsored by Palatin Technologies, Inc. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by Palatin Technologies, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).

Read the detailed description

A total of approximately 108 subjects at approximately five (5) centers within the United States (US), will be enrolled into the study for 8 weeks of treatment. Subjects who provide written informed consent and meet all initial eligibility criteria will enter into Screening. The subjects' historical and current medical data will be collected, reviewed, and recorded to be used as baseline values.

Enrolled subjects will begin the study and go through 2 treatment periods:

  • "Treatment Period 1" - 4 weeks of tirzepatide therapy only
  • "Treatment Period 2" - 4 weeks of combination therapy of bremelanotide, Placebo, or tirzepatide therapy.
02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity
  • Tirzepatide
  • Bremelanotide
  • BMI
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 108 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Palatin Technologies, Inc is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged between 18-65 years of age, inclusive at the time of consent.
  2. Have a (BMI) of 30.0 to 45.0 kg/m\^2 (inclusive) at screening.
  3. Female subjects must have a negative urine pregnancy test at screening, if of or be of non-childbearing potential. If the urine test is positive or cannot be confirmed as negative, then the subject must have a negative serum pregnancy test (hCG). Non-childbearing potential is defined as (by other than medical reasons):

    1. Age ≥ 50 years, no menses for at least one year, per subject self-report.
    2. Documented hysterectomy, bilateral tubal ligation, or bilateral oophorectomy.
  4. For female subjects who are Women of childbearing potential (WOCBP), subject must agree to abstain from heterosexual intercourse or use a highly effective (s) (with a failure rate of \<1% per year), as described in the protocol, during the treatment and follow-up and for at least 90 days after the last dose of bremelanotide. Hormonal-based contraception is to be employed for a minimum of 28 days prior to Day 0. Oral hormonal contraceptives should be combined estrogen and progesterone. If a progesterone-only oral contraceptive is used, then a second method of birth control should be used as well. Acceptable forms of contraception include:

    • Surgical sterilization of the subject or male partner;
    • FDA- or Health Canada-approved female hormonal contraceptives;
    • An IUD;
    • Essure® (transcervical sterilization);
    • "Double-barrier" contraception defined as:

      • condom + spermicide, or
      • condom + diaphragm (which is used with a spermicide).
  5. Female subjects must agree not to donate eggs (ova, oocytes) for any purpose during the treatment and follow-up and for at least 30 days after the last dose of BMT.
  6. Male subjects must agree to abstain from heterosexual intercourse or use double barrier protection with condom and spermicide with any WOCBP sexual partner from screening and continuing for at least 30 days after the last dose of BMT:

    a. Alternatively, documented sterilization confirmed by the absence of sperm in the ejaculate or ≥ one-year post-operative from vasectomy.

  7. Male subjects must agree not to donate sperm for at least 30 days after the last dose of BMT.
  8. Subjects must be willing to self-inject.
  9. Subjects must have the ability to complete the study in compliance with the protocol and all instructions.
  10. Subjects must have the ability to understand and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant, breastfeeding or plan to become pregnant.
  2. Have a known allergy or intolerance to Melanocortin peptides.
  3. Subjects with a positive Serum Antigen/Antibody Hepatitis Panel (Hep B and C) and antibody test Human Immunodeficiency Virus (HIV) antibody.

    Note: subject with positive antibody but negative PCR test for active Hepatitis C viral shedding will be allowed to participate in the study. Subjects with a positive surface antigen antibody or core antigen antibody will be allowed to participate in the study. Subjects with circulating hepatitis B surface antigen or have a positive PCR test for active hepatitis B virus will NOT be allowed to participate in the study.

  4. Subjects with active alcohol dependence and/or drug use (with Cannabis exception) as assessed by the Investigator will be excluded from the study.
  5. Have significant medical illnesses that cannot be adequately controlled with appropriate therapy and may obscure toxicity, dangerously alter drug metabolism, or compromise the subject's ability to participate in the trial, as determined by the Investigator, such as endocrinologic disorders accounting for obesity such as Cushing Disease, syndrome or monogenic obesity and exclusions of organ transplant recipients, those on wait lists, or those on anti-rejection medication as the potential effect on gastric emptying effecting pharmacokinetics.
  6. Has been on bremelanotide therapy (Vyleesi) within the past 6 months prior to screening date.
  7. Within the past three month, has used cyclosporine A, adrenocorticotropic hormones, long-term (> 20 mg qd or its equivalent for > 3 months), or cytotoxic agents.
  8. Has had body weight change (≥5%) or dieting attempts in the prior 90 days (per subject reported information) and Treatment Period 1.
  9. Use of Anti-Obesity Medication (AOM) within a 90-day period prior to screening (Note: subjects who have taken or are still taking tirzepatide may participate in study if exclusion criteria #8 has not been met. AOM medications will also include medications that are being used off-label for weight loss).
  10. Prior obesity or weight loss surgery or presence of gastrointestinal implant or bariatric surgery or other weight loss procedures within 2 years of screening (i.e. liposuction, abdominoplasty, intragastric balloon, cholecystectomy, etc.)
  11. Has ≥ 6.5 % or fasting glucose ≥126.0 mg/dL. (either test can be used to establish eligibility).
  12. Has type 1 diabetes.
  13. Has taken any experimental drug or therapy within 28 days / 5 half-lives of trial treatment or concurrently participating in another clinical trial.
  14. Has a history of clinically significant bradycardia and/or a heart rate less than 50 bpm at screening.
  15. Has multiple endocrine neoplasia syndrome type 2.
  16. Plan for blood donations during the study and within 30 days following completion of or early discontinuation from the trial.
  17. Planned bariatric surgery or planned major surgeries during the study time period.
  18. Has personal or family history of MEN 2 syndromes or Medullary Thyroid Cancer.
  19. Prior to tirzepatide component.
  20. Has hypertension (by medical history or by screening vital signs) and/or known cardiovascular disease.

    Note: If subject presents at screening with elevated blood pressure and no supporting evidence of hypertension; subject may wait approximately 1 hour to have blood pressure rechecked; if readings are still elevated, subject may return to the site approximately 24 hours later to have blood pressure rechecked.

  21. Is taking concomitant oral drugs that are dependent on threshold concentrations for efficacy (e.g., antibiotics) since bremelanotide slows gastric emptying and thus has the potential to reduce the rate and extent of absorption of concomitantly administered oral medications
  22. Has a diagnosis of type 2 diabetes
  23. Has Clinically significant abnormalities on ECG at Screening
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
108 participants (estimated)

Study arms

  • Active comparator
    tirzepatide and bremelanotide Combination Therapy

    Drug: bremelanotide · Drug: tirzepatide

  • Placebo comparator
    tirzepatide Monotherapy

    N=1

    Drug: tirzepatide

  • Placebo comparator
    bremelanotide Monotherapy

    Drug: bremelanotide

  • No intervention
    Placebo

Interventions

  • bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume

  • tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.

06

What researchers measure

Primary outcomes

  1. Percent change in body weight between treatment arms

    Percent change in patient weight from baseline (Visit 2/Day 1) to Visit 10 (Day 57) for the BMT/tirzepatide combination group compared to placebo

    Time frame: Change from the baseline (Visit 2/Day 1) to Visit 10 (Day 57)

Other outcomes

  1. Change in Body Weight

    Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57) in body weight (lbs.) between treatment arms

    Time frame: Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57)

  2. Change in Overall Appetite Suppression

    This exploratory endpoint is the change from Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57) in overall appetite suppression, as quantified by the Visual Analog Scale (VAS), between treatment arms. The Hunger and Satiety Visual Analogue Scales (VAS) yields a composite score ranging from 0 to 100, where 0 represents extreme hunger and 100 represents complete satiety. A higher VAS composite score indicates greater appetite suppression efficacy of the treatment.

    Time frame: Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57)

  3. Change in Appetite Suppression Subscales

    This exploratory endpoint assesses the change from Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57) in individual appetite suppression subscales (hunger, fullness, satiety, and prospective food consumption) between treatment arms. The Hunger and Satiety Visual Analogue Scales (VAS) comprise four distinct subscales, each quantifying specific aspects of appetite suppression: hunger, fullness, satiety, and prospective food consumption. These subscales permit independent assessment. * The hunger subscale, ranging from 0 to 100, quantifies subjective hunger, where 0 indicates minimal hunger and 100 maximal hunger. A score of 0 denotes optimal efficacy. * The fullness subscale, ranging from 0 to 100, quantifies subjective fullness, where 0 signifies absence of fullness and 100 complete fullness. A score of 100 denotes optimal efficacy. * The satiety subscale, ranging from 0 to 100, quantifies subjective satiety, where 0 signifies complete emptiness and 100 comp

    Time frame: Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57)

  4. Change in Percent Body Fat

    Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57) in percent body fat between treatment arms

    Time frame: Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57)

  5. Change in BMI

    Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57) in BMI between treatment arms

    Time frame: Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57)

  6. Change in Skeletal Muscle Mass

    This exploratory endpoint evaluates the change in skeletal muscle mass from Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57) between treatment arms. Skeletal muscle mass is quantified utilizing Bioelectrical Impedance Analysis (BIA) as the measurement modality. It is acknowledged that the observed range of skeletal muscle mass values is subject to inter-individual variability, influenced by factors including, but not limited to, age, gender, hydration status, recent dietary intake, and body temperature. Skeletal muscle mass assessment will be conducted in conjunction with the analysis of percent body fat and visceral fat level to provide a comprehensive evaluation of lean tissue composition.

    Time frame: Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57)

  7. Change in Visceral Fat Level

    This exploratory endpoint evaluates the change in visceral fat level from Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57) between treatment arms. Visceral fat is quantified utilizing Bioelectrical Impedance Analysis (BIA) as the measurement modality. It is acknowledged that the observed range of visceral fat values is subject to inter-individual variability, influenced by factors including, but not limited to, age, gender, hydration status, recent dietary intake, and body temperature. A visceral fat assessment will be conducted in conjunction with the analysis of percent body fat and skeletal muscle mass to provide a comprehensive evaluation of lean tissue composition.

    Time frame: Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57)

  8. Number of participants with abnormal laboratory tests results

    This exploratory endpoint evaluates the incidence of participants exhibiting clinically significant changes in laboratory test results from Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57), specifically focusing on deviations from reference ranges within the comprehensive metabolic panel (CMP) and lipid panel, between treatment arms.

    Time frame: Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57)

  9. Change in Neck and Waist Measurements

    This exploratory endpoint evaluates the change in neck and waist circumferences from Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57) between treatment arms. Circumferential measurements are obtained utilizing a calibrated tape measure with an imperial scale (inches). Neck circumference is determined by measuring the horizontal circumference at the level of the larynx. Waist circumference is assessed at the umbilicus in male participants, and at the midpoint between the inferior border of the sternum and the umbilicus in female participants. In female participants, hip circumference is additionally measured at the level of maximum gluteal protrusion.

    Time frame: Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57)

  10. Change in IIEF Domain Score

    This exploratory endpoint evaluates the change in the International Index of Erectile Function (IIEF) Erectile Function (EF) domain score from Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57) between treatment arms. The IIEF questionnaire, utilized for this assessment, yields an EF domain score ranging from 6 to 30, with higher scores indicative of improved erectile function.

    Time frame: Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57)

  11. Change in EDQ Score

    This exploratory endpoint evaluates the change in the Elements of Desire Questionnaire (EDQ) total score from Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57) between treatment arms. The Elements of Desire Questionnaire (EDQ) is the instrument employed for this assessment. The total score is derived from the mean of the nine EDQ items, each rated on a scale of 1 to 5, where 5 represents the maximum level of desire and satisfaction.

    Time frame: Change from the Visit 2 baseline and Treatment Period 2 baseline (Day 29) to Visit 10 (Day 57)

07

Study locations

4 sites
  • University Clinical Research-DeLand LLC, d/b/a Accel Research
    DeLand, Florida 32720, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405-5093, United States
  • Lynn Institute of Chattanooga
    Chattanooga, Tennessee 37404, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Feb 2025, 6 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 6 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2024
First posted
Aug 22, 2024
StartActual
Aug 5, 2024
Primary completionActual
Feb 5, 2025
CompletionEst.
Mar 31, 2025
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06565611
Lead sponsor
Palatin Technologies, Inc
Responsible party
Sponsor
First posted
Aug 22, 2024
Start date
Aug 5, 2024
Primary completion
Feb 5, 2025
Completion
Mar 31, 2025 (estimated)
Last update
Mar 6, 2025

Study contacts

Robert Jordan
study director · Palatin

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bremelanotide

Start the discussion